

Lecanemab eligibility checklist:

- Clinical diagnosis of AD-spectrum syndrome at severity of MCI or mild dementia
- MoCA 15 or greater, MMSE 22 or greater, SLUMS 16 or greater within 6 months of referral (exceptions may be considered)
- Does not have clinical diagnosis of LBD-spectrum or FTLD-spectrum syndrome
- Is not on anticoagulation, dual antiplatelet therapy, or chronic immunosuppressive medication
- Does not have other poorly controlled chronic medical, neurological, or psychiatric condition
- Able to comply with infusion visits every 2 weeks
- Has capacity to complete written informed consent to enroll in protocol
- CMP, B12, TSH, CBC, PT, PTT within 6 months of referral without abnormalities requiring further investigation
- MRI brain within 12 months of referral without exclusionary findings
- Elevated p-tau181/Abeta42 (Mayo Clinic labs), Abeta42/p-tau - 0.0105(t-tau) < 3.694 (ADMark), or amyloid PET suggesting elevated brain amyloid (optional prior to ATP referral)
- APOE genotyping (optional prior to ATP referral)